JIANGSU KANIONREAL BIOMEDICAL TECHNOLOGY CO., LTD. (20240261371). RHFGF21 FUSION PROTEIN, POLYNUCLEOTIDE ENCODING RHFGF21 FUSION PROTEIN, COMPOSITION CONTAINING RHFGF21 FUSION PROTEIN, AND USE OF RHFGF21 FUSION PROTEIN simplified abstract

RHFGF21 FUSION PROTEIN, POLYNUCLEOTIDE ENCODING RHFGF21 FUSION PROTEIN, COMPOSITION CONTAINING RHFGF21 FUSION PROTEIN, AND USE OF RHFGF21 FUSION PROTEIN

Organization Name

JIANGSU KANIONREAL BIOMEDICAL TECHNOLOGY CO., LTD.

Inventor(s)

Wei Xiao of Lianyungang, Jiangsu Province (CN)

Deshan Li of Lianyungang, Jiangsu Province (CN)

Dan Yu of Lianyungang, Jiangsu Province (CN)

Zhihang Liu of Lianyungang, Jiangsu Province (CN)

Zhenzhong Wang of Lianyungang, Jiangsu Province (CN)

Chengkai Yin of Lianyungang, Jiangsu Province (CN)

Xu Sun of Lianyungang, Jiangsu Province (CN)

RHFGF21 FUSION PROTEIN, POLYNUCLEOTIDE ENCODING RHFGF21 FUSION PROTEIN, COMPOSITION CONTAINING RHFGF21 FUSION PROTEIN, AND USE OF RHFGF21 FUSION PROTEIN - A simplified explanation of the abstract

This abstract first appeared for US patent application 20240261371 titled 'RHFGF21 FUSION PROTEIN, POLYNUCLEOTIDE ENCODING RHFGF21 FUSION PROTEIN, COMPOSITION CONTAINING RHFGF21 FUSION PROTEIN, AND USE OF RHFGF21 FUSION PROTEIN

The patent application describes a recombinant human fibroblast growth factor 21 (rhFGF21) fusion protein that is efficiently and solubly expressed using genetic engineering methods. This fusion protein, created by fusing rhFGF21 with an elastin-like protein (VPGXG), exhibits enhanced biological activity compared to wild-type rhFGF21.

• The fusion protein has high expression efficiency and can effectively reduce blood sugar levels in diabetic animals.
• It has a longer efficacy duration in lowering blood sugar levels compared to wild-type rhFGF21.
• The fusion protein is produced using a recombinant expression vector and cell, and can be used in pharmaceutical compositions.
• The method for producing the fusion protein involves genetic engineering techniques to optimize its expression and activity.
• The fusion protein offers a promising approach for treating diabetes and related conditions.

Potential Applications: - Treatment of diabetes and related metabolic disorders - Development of novel pharmaceuticals for regulating blood sugar levels - Research in the field of growth factors and metabolic pathways

Problems Solved: - Efficient and soluble expression of rhFGF21 fusion protein - Enhanced biological activity compared to wild-type rhFGF21 - Prolonged efficacy in reducing blood sugar levels

Benefits: - Improved treatment options for diabetes - Enhanced therapeutic effects on blood sugar regulation - Potential for developing new drugs with better efficacy and duration

Commercial Applications: Title: "Innovative rhFGF21 Fusion Protein for Diabetes Treatment and Beyond" This technology has significant commercial potential in the pharmaceutical industry for developing novel therapies for diabetes and related conditions. It could also lead to the creation of new drugs targeting metabolic pathways and growth factor signaling.

Questions about the technology: 1. How does the fusion of rhFGF21 with an elastin-like protein enhance its biological activity? 2. What are the specific mechanisms by which the rhFGF21 fusion protein reduces blood sugar levels in diabetic animals?

Original Abstract Submitted

a recombinant human fibroblast growth factor 21 (rhfgf21) fusion protein, a polynucleotide encoding the rhfgf21 fusion protein, a recombinant expression vector, a recombinant cell, a pharmaceutical composition and a kit containing the rhfgf21 fusion protein, a use of the rhfgf21 fusion protein, and a method for producing the rhfgf21 fusion protein. efficient and soluble expression is achieved using a genetic engineering method to obtain a rhfgf21-(vpgxg)fusion protein, wherein by means of fusion of rhfgf21 and an elastin-like protein (vpgxg)having an appropriate cycle number n, the resulting fusion protein has better biological activity than wild-type rhfgf21. moreover, experimental results indicate that the rhfgf21-(vpgxg)fusion protein has high expression efficiency, and can effectively reduce the blood sugar level in the body of a diabetic animal. in addition, compared with wild-type hfgf21, the fusion protein also has the advantage of a long efficacy duration in reducing the blood sugar level.